Literature DB >> 9835537

In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex.

C M Shoen1, O Choromanska, R C Reynolds, J R Piper, C A Johnson, M H Cynamon.   

Abstract

Three recently synthesized dihydrofolate reductase (DHFR) inhibitors designated SoRI 8890, 8895, and 8897 were evaluated for their in vitro activities against 25 isolates of Mycobacterium avium complex. The MICs at which 50 and 90% of isolates were inhibited were 1 and 2, 4 and 8, and 4 and 8 microgram/ml for SoRI 8890, 8895, and 8897, respectively. Although the addition of dapsone at 0.5 microgram/ml did not significantly enhance the in vitro activities of these compounds, their activities alone were comparable to, if not better than, results seen with other DHFR inhibitors, such as pyrimethamine or WR99210.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9835537      PMCID: PMC106045     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Trimethoprim-sulfamethoxazole treatment of Pneumocystis carinii pneumonia in adults.

Authors:  W K Lau; L S Young
Journal:  N Engl J Med       Date:  1976-09-23       Impact factor: 91.245

2.  Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Authors:  C Leport; F Raffi; S Matheron; C Katlama; B Regnier; A G Saimot; C Marche; C Vedrenne; J L Vilde
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965

3.  Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex.

Authors:  L M Shah; S C Meyer; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 4.  Beige mouse model for Mycobacterium avium complex disease.

Authors:  P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

5.  Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex.

Authors:  L M Shah; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

Review 6.  In vitro and in vivo results of brodimoprim and analogues alone and in combination against E. coli and mycobacteria.

Authors:  J K Seydel
Journal:  J Chemother       Date:  1993-12       Impact factor: 1.714

7.  Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole.

Authors:  W T Hughes; S Feldman; S K Sanyal
Journal:  Can Med Assoc J       Date:  1975-06-14       Impact factor: 8.262

8.  Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.

Authors:  J R Piper; C A Johnson; C A Krauth; R L Carter; C A Hosmer; S F Queener; S E Borotz; E R Pfefferkorn
Journal:  J Med Chem       Date:  1996-03-15       Impact factor: 7.446

9.  Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  G S Leoung; J Mills; P C Hopewell; W Hughes; C Wofsy
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

  9 in total
  2 in total

1.  Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.

Authors:  A'Lissa B Gerum; Jonathan E Ulmer; David P Jacobus; Norman P Jensen; David R Sherman; Carol Hopkins Sibley
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase.

Authors:  W J Suling; L E Seitz; V Pathak; L Westbrook; E W Barrow; S Zywno-Van-Ginkel; R C Reynolds; J R Piper; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.